MedTrace Logo

A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)

NCT01801163 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2015-04-16

No results posted yet for this study

Summary

This is a research study of a radiation treatment called stereotactic body radiotherapy (SBRT) plus a medicine called sorafenib. The purpose of this study is to evaluate the safety of SBRT plus Sorafenib to see what effects (good and bad) it has on the treatment of liver cancer.

Conditions

Interventions

DRUG

Sorafenib

Sorafenib x 2 weeks followed by Stereotactic Radiotherapy and then sorafenib until disease progression.

RADIATION

Stereotactic radiotherapy

Sorafenib x 2 weeks followed by Stereotactic Radiotherapy then Sorafenib until disease progression.

Sponsors & Collaborators

  • Indiana University

    lead OTHER

Principal Investigators

  • Higinia Cardenes, MD PHD · Indiana University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2014-08-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01801163 on ClinicalTrials.gov